Abrahão R, et al. - In this population-based study, researchers considered the influence of rituximab on the survival of children (0–19 years), adolescents, and young adults (AYAs, 20–39 years) with diffuse large B-cell lymphoma (DLBCL), including patients with human immunodeficiency virus (HIV) infection. From the Greater Bay Area Cancer Registry in California, data on 642 children and AYAs diagnosed with DLBCL during 2001–2014 were obtained. It was observed that the use of rituximab increased in children, AYAs and HIV patients from 2001–2007 to 2008–2014. A benefit of rituximab on the treatment of AYAs and HIV patients with DLBCL was suggested in this analysis. The worse survival of HIV-positive and uninsured patients is of concern. It should be carefully considered whether rituximab should be recommended more often for the front-line treatment of children and HIV-positive DLBCL patients.